Table 1.
Patients’ Characteristics and Pathological Stage and Factors.
| n = 152 | Overall % | |
|---|---|---|
| Mean age, years, (range) | 51.5 (32-87) | |
| Mean observation period, months, (range) | 64.7 (9.7-119.0) | |
| Menopausal status | ||
| Premenopausal | 75 | 49% |
| Postmenopausal | 77 | 51% |
| Chemotherapy | ||
| Yes | 127 | 84% |
| Neoadjuvant | (47) | (31%) |
| Postoperative | (80) | (53%) |
| No | 25 | 16% |
| Preoperative endocrine therapy | 2 | 1% |
| Types of chemotherapy | ||
| Anthracyclines and taxane | 106 | 70% |
| Anthracycline only | 3 | 2% |
| Taxane only | 18 | 12% |
| Postoperative endocrine therapy | ||
| Yes | 150 | 99% |
| (Tamoxifen) | (76) | (50%) |
| (Anastrozole) | (42) | (27%) |
| (Letrozole) | (28) | (18%) |
| (Exemestane) | (4) | 3% |
| No | 2 | 1% |
| LHRH agonist | 15 | 10% |
| Stage | ||
| Stage IIA | 25 | 16% |
| Stage IIB | 33 | 22% |
| Stage IIIA | 66 | 43% |
| Stage IIIB | 1 | 1% |
| Stage IIIC | 27 | 18% |
| Median invasive diameter, cm (range) | 2.8 (0.7-26.5) | |
| Invasive diameter ≥5 cm | 55 | 36% |
| Median lymph node metastases (range) | 3 (137) | |
| Four or more lymph node metastases | 68 | 44% |
| pCR after NAC | 3 | 7% |
| Nuclear Grade | ||
| 1, 2 | 56 | 37% |
| 3 | 96 | 63% |
| Ki67 | ||
| Ki67 ≧ 20% | 39 | 26% |
| Ki67 < 20% | 90 | 59% |
| unknown | 24 | 16% |
| Progeterone receptor | ||
| Positive | 126 | 83% |
| Negative | 26 | 17% |
| Cohort | ||
| 1 | 152 | 100% |
| (High) | (39) | (26%) |
| (Low) | (90) | (59%) |
| (Unknown) | (36) | (24%) |
| 2 | 0 | |
pCR, pathological complete response; NAC, neoadjuvant chemotherapy